Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




CT Lung Cancer Screening No Panacea for Smokers

By MedImaging staff writers
Posted on 02 Jul 2008
Screening for lung cancer with computed tomography (CT) imaging may help decrease lung cancer deaths in current and former smokers, but it will not protect them from other causes of death associated with smoking, according to a new study. More...


The recent research was published in the July 2008 issue of the journal Radiology. "Our study suggests that screening may be one way to reduce risk of death from lung cancer,” said the study's lead author, Pamela McMahon, Ph.D., a senior scientist from Massachusetts General Hospital and instructor in radiology at Harvard Medical School (both in Boston, MA, USA). "However, the number-one goal should still be to quit smoking, because it will reduce risk of death from many causes, including lung cancer.”

For the study, researchers from Harvard and the Mayo Clinic (Rochester, MN, USA), set out to determine the long-term effectiveness of CT screening for lung cancer by entering data from Mayo's helical CT screening study of 1,520 current and former smokers into the Lung Cancer Policy Model (LCPM), a comprehensive simulation model of lung cancer development, screening findings, treatment results, and long-term outcomes. Using the model allowed researchers to interpret available data while waiting for long-term randomized clinical trials to be completed.

"We used a carefully developed computer model of lung cancer to simulate individuals who smoke and/or develop lung cancers and go on to get screened or treated,” Dr. McMahon said. "It's sort of like the computer game ‘The Sims,' except there are no graphics, and smoking and lung cancer are the main events.”

The LCPM projections showed that, at six-year follow-up, the patients who had undergone five annual screenings had an estimated 37% relative increase in lung cancer detection, compared with those who had not been screened. The relative reduction in lung cancer-specific mortality was 28%. However, reduction in all-cause mortality was only 4%. Fifteen-year follow-up showed relative reductions in lung cancer-specific mortality of 15% and all-cause mortality of 2%.

"Our study fills in a piece of the puzzle but does not solve it,” Dr. McMahon said. "We are hopeful that randomized trials conducted by the [U.S.] National Cancer Institute will show a benefit from screening. Until then, patients should think carefully about undergoing a test that has no direct evidence of benefit.”


Related Links:
Massachusetts General Hospital
Mayo Clinic

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Gas Analyzer
GE SAM
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.